ProMetic Life Sciences Inc. provided tan update on its clinical development and commercial milestones scheduled for completion in fourth quarter of 2014. The Investigational New Drug (IND) application for ProMetic's intravenous immunoglobulin (IVIG) was filed in December 2014 with the American Food and Drug Administration (FDA) and patients' enrolment is expected to commence during this quarter. The enrolment of patients for the Plasminogen Phase 1 clinical trial is progressing as expected.

No serious adverse events were reported in the initial part of the PBI-4050 phase 1b/II trial in patients with Diabetic Kidney Disease (DKD). Finally, the completion of the previously announced license and strategic agreement with Generium on December 21, 2014 as well as the achievement of a development milestone in late December 2014 alone contributed approximately $9 Million to fourth quarter of 2014.